We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.84%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.85B
AUM Growth
+$135M
Cap. Flow
-$725M
Cap. Flow %
-39.12%
Top 10 Hldgs %
58.55%
Holding
374
New
79
Increased
68
Reduced
92
Closed
116

Top Buys

Rank Stock Value
1
BIOA
BioAmber Inc.
BIOA
+$5.55M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.2M
3
OTIC
Otonomy, Inc.
OTIC
+$3.92M
4
BLRX
BioLineRX
BLRX
+$3.37M
5
SLS icon
SELLAS Life Sciences
SLS
+$2.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$62.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$59.7M
3
AMGN icon
Amgen
AMGN
+$35.8M
4
LLY icon
Eli Lilly
LLY
+$15.7M
5
BIIB icon
Biogen
BIIB
+$5.67M

Sector Composition

Rank Sector Weight
1 Healthcare 6.29%
2 Materials 0.25%
3 Financials 0.16%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
51
Ionis Pharmaceuticals
IONS
$8.93B
$4.65M 0.25%
+115,694
New +$5.2M
MTFB
52
DELISTED
Motif Bio plc ADRs
MTFB
$4.6M 0.25%
755,875
-91,951
-11% -$576K
SGEN
53
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
$4.34M 0.23%
+690
New +$43.1K
AMRN
54
CALL
Amarin Corp
AMRN
$297M
$4.27M 0.23%
668
+51
+8% +$3.24K
HALO icon
55
CALL
Halozyme
HALO
$9.88B
$4.21M 0.23%
3,248
+540
+20% +$6.83K
EXEL icon
56
CALL
Exelixis
EXEL
$13.9B
$3.68M 0.2%
1,700
-83
-5% -$1.69K
PRTA icon
57
CALL
Prothena Corp
PRTA
$448M
$3.68M 0.2%
660
+170
+35% +$8.93K
MON
58
CALL
DELISTED
Monsanto Co
MON
$3.54M 0.19%
313
– –
SPNC
59
PUT
DELISTED
Spectranetics Corp
SPNC
$3.47M 0.19%
+1,191
New +$31.7K
OTIC
60
DELISTED
Otonomy, Inc.
OTIC
$3.42M 0.18%
278,840
+268,840
+2,688% +$3.92M
MNKD icon
61
PUT
MannKind Corp
MNKD
$1.19B
$3.41M 0.18%
23,014
+21,446
+1,368% +$56.3K
BIOA
62
DELISTED
BioAmber Inc.
BIOA
$3.39M 0.18%
+1,460,859
New +$5.55M
SAGE
63
PUT
DELISTED
Sage Therapeutics
SAGE
$3.28M 0.18%
462
+360
+353% +$21.1K
LJPC
64
CALL
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.14M 0.17%
1,053
-634
-38% -$16.2K
TSRO
65
CALL
DELISTED
TESARO, Inc.
TSRO
$3.11M 0.17%
202
-1,664
-89% -$271K
FOLD
66
CALL
DELISTED
Amicus Therapeutics
FOLD
$3.1M 0.17%
4,353
-5,863
-57% -$37.1K
BLRX
67
BioLineRX
BLRX
$12M
$3.02M 0.16%
+5,236
New +$3.37M
BNBX
68
DELISTED
BNB PLUS CORP
BNBX
$2.93M 0.16%
3
-1
-25% -$1.08M
CHRS icon
69
PUT
Coherus Oncology
CHRS
$217M
$2.83M 0.15%
1,336
+424
+46% +$10.4K
EIGR
70
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.73M 0.15%
7,964
-54
-0.7% -$18.6K
PALI icon
71
Palisade Bio
PALI
$341M
$2.72M 0.15%
+6
New +$2.29M
ACHN
72
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$2.68M 0.14%
6,363
-3,724
-37% -$15.5K
SRRA
73
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.67M 0.14%
43,657
+20,136
+86% +$1.17M
RARE icon
74
PUT
Ultragenyx Pharmaceutical
RARE
$2.46B
$2.67M 0.14%
+394
New +$30K
INDP icon
75
Indaptus Therapeutics
INDP
$243M
$2.65M 0.14%
230
– –
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sabby Management held 374 positions worth $1.85B, up 7.8% from $1.72B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $725M in Q1 2017, closing 116 positions and reducing 92 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $62.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.3% of assets, down from 18% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in BioAmber Inc. worth $3.39M.

  • Sabby Management's largest Q1 2017 buy was BioAmber Inc.: 1,460,859 shares worth $3.39M.
  • Sabby Management added most to Otonomy, Inc. in Q1 2017, an estimated $3.92M increase.
  • Sabby Management's biggest Q1 2017 reduction was Amgen, cutting an estimated $35.8M.
  • Sabby Management fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $62.4M.
  • Sabby Management's ten largest holdings make up 59% of its $1.85B portfolio in Q1 2017.
  • Sabby Management opened 79 new positions and closed 116 in Q1 2017.
  • Sabby Management's portfolio value rose 7.8% quarter-over-quarter to $1.85B.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.